clinical trial · NCT07452198
A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
Genrix (Shanghai) Biopharmaceutical Co., Ltd.·phase3·recruiting·n = 358
Multiple MyelomaGR1803 injectionDaratumumabPomalidomideDexamethasone
brief summary
The purpose of this study is to compare the efficacy of GR1803 Injection with daratumumab in combination with pomalidomide and dexamethasone (DPd).
started
Mar 9, 2026
primary completion
Mar 1, 2029
completion
Mar 1, 2030
last updated
Mar 25, 2026
official title
A Phase 3, Multicenter, Open-Label, Randomized Study Comparing GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy Including Lenalidomide and Proteasome Inhibitors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol